Clinical Trials Directory

Trials / Completed

CompletedNCT06236698

The Diagnostic Performance of 24-hour Urinary Aldosterone for Primary Aldosteronism

Accuracy of 24-hour Urinary Aldosterone Testing in Diagnosing Primary Aldosteronism and Analysis of Drug Interference Factors

Status
Completed
Phase
Study type
Observational
Enrollment
999 (actual)
Sponsor
Zhiming Zhu · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

This is an observational study to define the cut-off value of 24-hour urinary aldosterone for diagnosing primary aldosteronism in hypertensive patients in our center. Plasma aldosterone and renin measurements are subject to significant intra-individual variability, including variation related to posture, time of day and sodium balance. Aldosterone secretion is not constant and may be subject to diurnal variation. As such one-off testing of ARR, does not consider the salt status of the individual necessitating repetition of tests to ensure false negative or false positive test results are ruled out. The value of accumulated aldosterone in a 24-hour sample has the advantage that it does not depend on circadian variation. This study will help establish the positivity rates of 24-hour urine aldosterone, and test the robustness of current standard guidelines for primary aldosteronism screening and case confirmation. Previous studies reported that primary aldosteronism is associated with a higher risk of CV complications and a higher prevalence of target organ damage. Also, previous studies reported on the association of echocardiographic parameters with circulating or urinary aldosterone. Therefore, we intent to investigate the independent associations of different target organ damage with the urinary excretion of aldosterone.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TEST24-hour urinary aldosterone measurementCollect 24-hour urine sample from each participant and complete the detection of urinary aldosterone content.

Timeline

Start date
2022-03-01
Primary completion
2024-03-30
Completion
2024-10-30
First posted
2024-02-01
Last updated
2025-04-16

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06236698. Inclusion in this directory is not an endorsement.